NCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
Clinical Trials
101 trialsNCT07313891 2026-03-17
BOOST
Relmada Therapeutics, Inc.
Phase 3 Withdrawn
NCT07342517 2026-03-17
RESCUE
Relmada Therapeutics, Inc.
Phase 3 Withdrawn
NCT06884254 2025-10-14
EGC102
EirGenix, Inc.
Phase 3 Withdrawn
NCT06254742 2025-08-07
A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Withdrawn
NCT06795178 2025-04-27
KATANA E3M
Foresee Pharmaceuticals Co., Ltd.
Phase 3 Withdrawn
NCT06795191 2025-04-27
KATANA E6M
Foresee Pharmaceuticals Co., Ltd.
Phase 3 Withdrawn
NCT01345084 2025-03-28
NICAP
Eurofarma Laboratorios S.A.
Phase 3 Withdrawn
NCT00733122 2025-03-03
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT03632798 2025-02-12
ACSCO
Cordgenics, LLC
Phase 3 Withdrawn
NCT06370871 2024-07-17
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
Boehringer Ingelheim
Phase 3 Withdrawn
NCT06093503 2024-06-26
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
AbbVie
Phase 3 Withdrawn
NCT06232707 2024-05-31
ALUMMINATE
Celgene
Phase 3 Withdrawn
NCT06205290 2024-04-02
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
NCT04760288 2024-01-05
AcceleRET-MTC
Hoffmann-La Roche
Phase 3 Withdrawn
NCT05712941 2023-11-03
Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer
EQRx International, Inc.
Phase 3 Withdrawn
NCT05261646 2023-09-28
A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Withdrawn
NCT05791097 2023-07-24
AdvanTIG-306
Novartis
Phase 3 Withdrawn
NCT04466917 2023-07-03
A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
Amgen
Phase 3 Withdrawn
NCT05564338 2023-06-07
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
BeiGene
Phase 3 Withdrawn
NCT05431179 2023-04-21
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Oncternal Therapeutics, Inc
Phase 3 Withdrawn
NCT04943627 2022-10-05
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Agenus Inc.
Phase 3 Withdrawn
NCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT04796922 2022-07-18
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
Incyte Corporation
Phase 3 Withdrawn
NCT04465734 2022-05-05
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT04806945 2022-05-05
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT04849715 2022-04-29
CITADEL-310
Incyte Corporation
Phase 3 Withdrawn
NCT03905902 2021-12-23
VITALIA
Sotio Biotech Inc.
Phase 3 Withdrawn
NCT04859582 2021-12-16
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT04572776 2021-11-09
Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain
Sorrento Therapeutics, Inc.
Phase 3 Withdrawn
NCT03658213 2021-05-10
LARES
AstraZeneca
Phase 3 Withdrawn
NCT04151719 2021-05-07
An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Bausch Health Americas, Inc.
Phase 3 Withdrawn
NCT02576275 2021-03-17
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
SecuraBio
Phase 3 Withdrawn
NCT04671420 2020-12-17
Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT02597465 2020-12-14
A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507
Sun Pharma Advanced Research Company Limited
Phase 3 Withdrawn
NCT00551239 2020-10-19
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
CTI BioPharma
Phase 3 Withdrawn
NCT00576225 2020-10-19
CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
CTI BioPharma
Phase 3 Withdrawn
NCT00577161 2020-10-05
Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
CTI BioPharma
Phase 3 Withdrawn
NCT03740945 2020-07-31
Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer
EndoCeutics Inc.
Phase 3 Withdrawn
NCT03628053 2020-07-09
OBERON
Novartis
Phase 3 Withdrawn
NCT04203511 2020-06-09
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
Incyte Corporation
Phase 3 Withdrawn
NCT04006691 2020-05-07
Retreatment
UroGen Pharma Ltd.
Phase 3 Withdrawn
NCT03881111 2020-02-11
KEYNOTE-590
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT03699176 2020-01-18
ASTEROID 7
Bayer
Phase 3 Withdrawn
NCT03342352 2019-12-20
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
Incyte Corporation
Phase 3 Withdrawn
NCT03811418 2019-11-26
ATTILA
iOMEDICO AG
Phase 3 Withdrawn
NCT03529084 2019-11-22
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
Novartis
Phase 3 Withdrawn
NCT03386838 2019-04-18
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
Bristol-Myers Squibb
Phase 3 Withdrawn
NCT03717038 2019-02-04
Sym004 Versus TAS-102 in Patients With mCRC
Symphogen A/S
Phase 3 Withdrawn
NCT03334487 2018-12-26
Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
AbbVie
Phase 3 Withdrawn